Stock Analysis Jan. 26th: Broadcom, Monster, Celgene, Valero
Momenta Pharmaceuticals Inc.(NASDAQ:MNTA): Momenta Pharma price target cut to $17 from $21 at BofA/Merrill
Monster Worldwide, Inc.(NYSE:MWW): Monster Worldwide weakness a buying opportunity, says SunTrust
Celgene Corporation(NASDAQ:CELG): Citigroup said Celgene’s fundamentals remain solid and 2012 Revlimid guidance appears achievable. The firm sees upside to EPS driven by operating margins, buybacks, and lower tax rate. Shares are Buy rated.
Valero Energy Corp.(NYSE:VLO): Argus believes that Valero’s stock doesn’t fully reflect the recent rebound in the company’s businesses, or of expected increases in its earnings. The firm maintains a Buy rating on the stock.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Derek Hoffman at email@example.com
To contact the editor responsible for this story: Damien Hoffman at firstname.lastname@example.org